Clinical trial · Interventional
Medical Imaging of Cachexia
A Pilot Bioimaging Trial of Cancer Cachexia
NCT04127981CI-TRIAL-00064915unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a pilot trial using 18F-FDG PET and DXA scans to determine whether these investigations are objective tools to assess cachexia.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer Cachexia | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 18F-FDG PET + Dexa Scan | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Patients with cancer cachexia
- description
- 20 patients with advanced/metastatic colorectal, non-small cell lung cancer (NSCLC), or pancreatic cancer with documented cachexia.
- interventionNames
- Diagnostic Test: 18F-FDG PET + Dexa Scan
- type
- ACTIVE_COMPARATOR
- label
- Patients without cancer cachexia
- description
- 20 patients with advanced/metastatic colorectal, non-small cell lung cancer (NSCLC) or pancreatic cancer without cachexia.
- interventionNames
- Diagnostic Test: 18F-FDG PET + Dexa Scan
Primary outcomes (1)
- measure
- Correlation of a clinical diagnosis of cachexia with the metabolic activity of brown adipose tissue, bone density and muscle mass.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with malignant disease; * ECOG Performance score of 0-2; * Age ≥ 18 years; * Life expectancy of \>4 months at screening; * Cachexia patient group only: Fulfils diagnostic criteria for cachexia: unintentional weight loss more than 5% over the previous 6 months, or more than 2% in individuals with a decreased body-mass index of \<20kg/m2, or skeletal muscle wasting (sarcopenia). Exclusion Criteria: Patients with uncontrolled Diabetes Mellitus; * Psychological unstable persons presumed unfit to perform the investigations; * Persons unable to lie or sit still for 1-2 hours; * Pregnant patients; * Patients who received high doses of radiotherapeutic radiation of the neck and/or upper chest in their medical history limiting nutritional intake; * Patients who are receiving any chemotherapeutic agents which is limiting nutritional intake; * Persons that received cervical or thoracic sympathectomy or have a nerve dysfunction which is likely to influence sympathetic nerves; * The use of medication that influences the sympathetic nerve system: ß-blockers, α-blockers, central anti-hypertensives, certain anti-depression drugs (MAO inhibitors, tricyclic antidepressives), reserpine, cocaine, calcium channel blockers, labetalol, and certain tranquillizers (fenothiazines).
References
Publications (0)
Data not yet available
No reference posted for this study.